Published by Misasa Medical Center, Okayama University Medical School
Published by Misasa Medical Center, Okayama University Medical School

<Formerly known as>
岡大三朝分院研究報告 (63号-72号) 環境病態研報告 (57号-62号)
岡山大学温泉研究所報告 (5号-56号) 放射能泉研究所報告 (1号-4号)

<Availability>
Some items are not available because of decision by its author or publisher.

Effects of spa therapy on reduction of the costs of the drugs used for the treatment of asthma in the elderly in relation to disease severity

芦田 耕三 岡山大学医学部・歯学部附属病院三朝医療センター 内科
光延 文裕 岡山大学医学部・歯学部附属病院三朝医療センター 内科
保崎 泰弘 岡山大学医学部・歯学部附属病院三朝医療センター 内科
濱田 全紀 岡山大学医学部・歯学部附属病院三朝医療センター リハビリテーション科
岩垣 尚史 岡山大学医学部・歯学部附属病院三朝医療センター 内科
藤井 誠 岡山大学医学部・歯学部附属病院三朝医療センター 内科 
高田 真吾 岡山大学医学部・歯学部附属病院三朝医療センター 内科 
谷崎 勝朗 岡山大学医学部・歯学部附属病院三朝医療センター 内科
抄録
Costs of drugs used for the treatment for 1 year were compared before and after spa therapy in 16 patients with asthma in relation to disease severity. Asthma severity was classified as : stage 1 (intermittent), 2 (mild persistent), 3(moderate persistent), and 4(severe persistent). 1. The total cost of drugs used for each pa-tient for 1 year clearty decreased in all groups. The % decrease of the costs of drugs in each group was 27.2% in patients with stage 1, 43.5% in those with stage 2 and 34.1% in those with stage 3-4 (mean 34.5% ). The reduction of the cost of bronchodilators was predominant in patients with stage 3-4, and the decrease in the cost of corticosteroids predominant in those with stage 2. The reduction of costs of antiallertgics, mucolytics, and antibiotics was predominant in patients with stage 2 and stage 3-4. The % reduction in the cost of corticostroids was remarkable in patients with stage 2. The % decrease in the costs of mucolytics and antibiotics was predomi-nant in patients with stage 2 and stage 3-4. The results obtained here suggest that the costs of drugs used for asthmatics could be reduced by long-term spa therapy, and the reduction of the costs was larger as asthma stage became more severe.
キーワード
asthma
spa therapy
costs
bronchodilators
corticostreroids
antiallergics
ISSN
1348-1258
NCID
AA11840279